Cargando…

Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the metabolic pathway of 5-fluorouracil (5-FU) and other fluoropyrimidines to inactive compounds. For this reason, severe, life-threatening toxicities may occur in patients with deficient DPD activity when a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Del Re, Marzia, Michelucci, Angela, Di Leo, Angelo, Cantore, Maurizio, Bordonaro, Roberto, Simi, Paolo, Danesi, Romano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556010/ https://www.ncbi.nlm.nih.gov/pubmed/26330892 http://dx.doi.org/10.1186/s13167-015-0039-x

Ejemplares similares

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
por: Ridge, S. A., et al.
Publicado: (1998)

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase
por: Merloni, Filippo, et al.
Publicado: (2019)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

In Vitro Assessment of Fluoropyrimidine-Metabolizing Enzymes: Dihydropyrimidine Dehydrogenase, Dihydropyrimidinase, and β-Ureidopropionase
por: Hishinuma, Eiji, et al.
Publicado: (2020)

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
por: Ruzzo, A, et al.
Publicado: (2017)

The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
por: Abbasian, Mohammad Hadi, et al.
Publicado: (2020)

Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
por: Wigle, Theodore J., et al.
Publicado: (2021)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
por: Gross, Eva, et al.
Publicado: (2008)

A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy
por: Del Re, Marzia, et al.
Publicado: (2014)

The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine)
por: Challoob, Muhtada A, et al.
Publicado: (2023)

Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies
por: IZUMI, HIROKI, et al.
Publicado: (2015)

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
por: Del Re, Marzia, et al.
Publicado: (2019)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins
por: Arrigoni, Elena, et al.
Publicado: (2017)

Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
por: Ichikawa, W, et al.
Publicado: (2003)

Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study
por: Detailleur, Stephanie, et al.
Publicado: (2021)

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
por: Vogel, Wendy H., et al.
Publicado: (2020)

Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
por: Patel, Girijesh Kumar, et al.
Publicado: (2018)

Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction
por: Medwid, Samantha, et al.
Publicado: (2023)

The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines
por: De Mattia, Elena, et al.
Publicado: (2019)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
por: McLeod, H. L., et al.
Publicado: (1998)

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door
por: Donadio, Mauro Daniel Spina, et al.
Publicado: (2022)

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer
por: Horiguchi, J, et al.
Publicado: (2002)

A ferredoxin-dependent dihydropyrimidine dehydrogenase in Clostridium chromiireducens
por: Wang, Feifei, et al.
Publicado: (2020)

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase
por: Kang, Jihyun, et al.
Publicado: (2021)

Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023)

PREEMPTIVE PHARMACOGENETIC TESTING: EXPLORING THE KNOWLEDGE AND PERSPECTIVES OF UNITED STATES PAYERS
por: Keeling, Nicholas J., et al.
Publicado: (2017)

Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing
por: Duarte, Julio D., et al.
Publicado: (2021)

Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
por: Jennings, Barbara A., et al.
Publicado: (2013)

DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
por: Martens, Forike K., et al.
Publicado: (2020)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity
por: Nagaharu, Keiki, et al.
Publicado: (2016)

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy
por: Diasio, Robert B., et al.
Publicado: (2022)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Correction: Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
por: Jennings, Barbara A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7oovvcc3jdavg1h84pdfvtv8gm